+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Humoral immune response to human cytomegalovirus in patients undergoing percutaneous transluminal coronary angioplasty



Humoral immune response to human cytomegalovirus in patients undergoing percutaneous transluminal coronary angioplasty



Clinical and Diagnostic Laboratory Immunology 6(1): 45-49



Possible causal relations between prior human cytomegalovirus (HCMV) infection and atherosclerosis and between HCMV reactivation and restenosis after coronary angioplasty have been suggested. We investigated patterns of antibodies directed to HCMV in 112 patients undergoing percutaneous transluminal coronary angioplasty (PTCA) and in a group of sex- and age-matched controls (blood donors without evidence of atherosclerosis). Levels of antibodies to HCMV were measured by enzyme-linked immunosorbent assay (ELISA) of serum samples drawn before and 5 weeks after PTCA. To further differentiate the humoral immune response, we specifically tested antibody reactivity towards four single HCMV proteins (IE2, p52, pp150, and pp65) by recombinant ELISAs. We found that 73% of PTCA patients and 69% of sex- and age-matched controls were seropositive for HCMV (odds ratio, 1.2 (not significant)). The corresponding odds ratios for matched pairs ranged in the recombinant ELISAs from 1.2 to 1.4. Patients had more often high titers of anti-HCMV antibodies (11 versus 4%; odds ratio = 3.3 (0.9 to 15.2); P = 0.052) and high titers of anti-pp150 antibodies (13 versus 4%; odds ratio = 6.0 (1.3 to 38.8); P = 0.008). Anti-HCMV immunoglobulin M antibodies were not detected in any patient. There was no evidence of acute HCMV reactivation after PTCA, since the titers of antibodies to the investigated recombinant proteins did not increase at 5 weeks after PTCA. Our results show a limited association between prior HCMV infection and coronary artery disease. We infer that positive anti-HCMV titers are not a major risk factor at the time of disease manifestation. However, this study cannot rule out a possible role of HCMV at earlier stages of the atherosclerotic process. Recombinant ELISAs provide a valuable tool for investigating the antiviral immune response.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 010769028

Download citation: RISBibTeXText

PMID: 9874662


Related references

Serological response to human cytomegalovirus in patients undergoing percutaneous transluminal coronary angioplasty. Circulation 94(8 Suppl. ): I711, 1996

A beta chemokine -induced antigen-independent cellular and not a humoral immune response can be stimulated after stent percutaneous transluminal coronary angioplasty. Journal of the American College of Cardiology 39(5 Suppl. A): 54A, 2002

Outcome in patients admitted with extensive myocardial infarction to a hospital without angioplasty facilities transferred to a percutaneous transluminal coronary angioplasty centre for emergency percutaneous transluminal coronary angioplasty. European Heart Journal 17(ABSTR Suppl. ): 515, 1996

Influence of a nonionic, iso-osmolar contrast medium (iodixanol) versus an ionic, low-osmolar contrast medium (ioxaglate) on major adverse cardiac events in patients undergoing percutaneous transluminal coronary angioplasty: A multicenter, randomized, double-blind study. Visipaque in Percutaneous Transluminal Coronary Angioplasty [VIP] Trial Investigators. Circulation 101(2): 131-136, 2000

Percutaneous transluminal coronary angioplasty in African-American patients (the National Heart, Lung, and Blood Institute 1985-1986 Percutaneous Transluminal Coronary Angioplasty Registry). American Journal of Cardiology 73(16): 1141-1146, 1994

Percutaneous cardiopulmonary bypass support in high-risk patients undergoing percutaneous transluminal coronary angioplasty. American Journal of Cardiology 64(19): 1258-1263, 1989

Radiation doses to patients undergoing coronary angiography and percutaneous transluminal coronary angioplasty. Radiation Protection Dosimetry 103(2): 149-154, 2003

Coronary stenting in patients undergoing percutaneous transluminal coronary angioplasty during acute myocardial infarction. American Journal Of Cardiology. 77(9): 685-689, 1996

X-ray dose to the skin in patients undergoing percutaneous transluminal coronary angioplasty. Catheterization and Cardiovascular Interventions 50(3): 300-306, 2000

Endothelin-1 level in patients undergoing percutaneous transluminal coronary angioplasty. European Heart Journal 16(ABSTR Suppl. ): 491, 1995

Percutaneous transluminal coronary angioplasty in patients undergoing chronic dialysis. Journal of Interventional Cardiology 6(4): 293-296, 1993

Radiation exposure to patients undergoing percutaneous transluminal coronary angioplasty. American Journal of Cardiology 59(9): 996-997, 1987

Plasma endothelin levels in patients with coronary artery disease undergoing percutaneous transluminal coronary angioplasty. Japanese Circulation Journal 54(8): 945, 1990

Role of percutaneous transluminal coronary angioplasty in the treatment of unstable angina. Report from the National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty and Coronary Artery Surgery Study Registries. American Journal of Cardiology 53(12): 131c-135c, 1984

Circulating immunoreactive endothelin in patients undergoing percutaneous transluminal coronary angioplasty. European Heart Journal 16(ABSTR Suppl. ): 493, 1995